Diagnosis, staging, and surveillance of pancreatic cancer

American Journal of Roentgenology

Volumn 180, Issue 5, 2003, Pages 1311-1323

  Tamm, Eric P ^a   Silverman, Paul M ^a   Charnsangavej, Chusilp ^a   Evans, Douglas B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER STAGING; HUMAN; PANCREAS CANCER; PATHOLOGY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0037404607     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.180.5.1801311     Document Type: Article

References (83)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47
2. Simon B, Printz H. Epidemiological trends in pancreatic neoplasias. Dig Dis 2001;19:6-14
3. Parkin DM, Muir CS. Cancer incidence in five continents: comparability and quality of data. IARC Sci Publ 1992;120:45-173
4. Weiderpass E, Partanen T, Kaaks R, et al. Occurrence, trends and environment etiology of pancreatic cancer. Scand J Work Environ Health 1998;2:165-174
5. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer: Intemational Pancreatitis Study Group. N Engl J Med 1993;328:1433-1437
6. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998;7:67-91
7. Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J 2001;7:266-273
8. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554
9. Day JD, Digiuseppe JA, Yeo C, et al. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 1996;27:119-124
10. Ghadimi BM, Schrock E, Walker RL, et al. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999;154:525-536
11. Poremba C, Yandell DW, Huang Q, et al. Frequency and spectrum of p53 mutations in gastric cancer: a molecular genetic and immunohistochemical study. Virchows Arch 1995;426:447-455
12. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-3033
13. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-1734
14. Kloppel G, Hruban RH, Longnecker DS. Ductal adenocarcinoma of the pancreas. In: Hamilton SR, Aaltonen LA, eds. Pathology and genetics: tumours of the digestive system. Lyon: IARC, 2000:221-230
15. Bommer G, Friedel U, Heitz PU, Koppel G. Pancreatic PP cell distribution and hyperplasia: immunocytochemical morphology in normal pancreas, chronic pancreatitis, and pancreatic carcinoma. Virchows Arch A Pathol Anat Histopathol 1980;387:319-331
16. Hoorens A, Lemoine NR, McLellan E, et al. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol 1993;143:685-698
17. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma: imaging techniques and tumor markers. Pancreas 1992;7:66-86
18. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-355
19. Lundin J, Roberts PJ, Kuusela P, Haglund C. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Anticancer Res 1995;15:2181-2186
20. Iwao T, Hiyama E, Yok T, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. J Natl Cancer Inst 1997;89:1621-1623
21. Sobin LH, Wittekind C, eds. TNM classification of malignant tumours, 6th ed. Baltimore: Wiley-Liss. 2002
22. [No authors listed] Exocrine pancreas. In: Freene FL, Page DL, Felming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002:157-164
23. Evans DB, Lee JE, Pisters PWT. Pancreati-coduodenectomy (Whipple operation) and total pancreatectomy for cancer. In: Baker RJ, Fischer JF, eds. Mastery of Surgery, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1299-1318
24. Traverso LW, Longmire WP. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146:959-962
25. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. Ann Surg 1990;211:447-458
26. Lowenfels AB, Maisonneuve P, Boyle P. Epidemiology of pancreatic cancer. In: Howard J, Idezuki Y, Ihse I, et al., eds. Surgical disease of the pancreas, 3rd ed. Baltimore: Williams and Wilkins, 1998:433-437
27. Douglass HJ, Kim S, Meropol N, Neoplasms of the exocrine pancreas. In: Holland J, Frei EI, Bast RJ, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine, 4th ed. Baltimore: Williams and Wilkins, 1997:1989-2018
28. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1126-1161
29. Bold PJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999;3:233-243
30. Harrison LE, Klimstra D, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma: a contraindication for resection? Ann Surg 1996;224:342-349
31. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903
32. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-1585
33. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413
34. Di Costanzo F, Sdrobolini A, Carlini P, et al. Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic cancer (APC): a GOIRC randomized phase II trial. 37th Annual scientific meeting of Clinical Oncology. San Francisco: Society of Clinical Oncology, 2001:154a
35. Fung MC, Sakata T. What's new in pancreatic cancer treatment? J Hepatobiliary Pancreat Surg 2002;9:61-75
36. Sasson AR, Wetherington RW, Hoffman JP, et al. Neoadjuvant therapy for adenocarcinoma of the pancreas: histopathologic effect and analysis of outcome. 37th Annual scientific meeting of Clinical Oncology. San Francisco: Society of Clinical Oncology, 2001:156a
37. Hietaniemi K, Karkkainen P, Kiviluoto T, Kivisaari L, Elomaa I, Joensuu T. Phase I-II trial of twice-weekly gemcitabine (GEM) and concomitant irradiation in patients (Pts) with locally advanced pancreatic cancer. 37th Annual scientific meeting of Clinical Oncology. San Francisco: Society of Clinical Oncology, 2001:142b
38. Wolff RA, Chiao P, Lenzi R, et al. Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 2000;18:43-56
39. Wayne JD, Abdalla EK, Wolff RA, Crane CH, Pisters PW, Evans DB. Localized adenocarcinoma of the pancreas; the rationale for reoperative chemoradiation. Oncologist 2002;7:34-45
40. Kim T, Murakami T, Takahashi S, et al. Pancreatic CT imaging: effects of different injection rates and doses of contrast material. Radiology 1999;212:219-225
41. Tublin M, Tessler F, Cheng SL. Effect of injection rate of contrast medium on pancreatic and hepatic helical CT. Radiology 1999;210:97-101
42. Silvemian PM, Brown B, Wray H, et al. Optimal contrast enhancement of the liver using helical (spiral) CT: value of SmartPrep. AJR 1995;164:1169-1171
43. Winter TC III, Freeny PC, Nghiem HV. Extrapancreatic gastrinoma localization: value of arterialphase helical CT with water as an oral contrast agent. AJR 1996;166:51-52
44. Richter GM, Simon C, Hoffmann V, et al. Hydrospiral CT of the pancreas in thin section technique [in German]. Radiologe 1996;36:397-405
45. Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998;206:373-378
46. Ichikawa T, Haradome H, Hachiya J, et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997;202:655-662
47. Nishiharu T, Yamashita Y, Abe Y, et al. Local extension of pancreatic carcinoma: assessment with thin-section helical CT versus with breath-hold fast MR imaging - ROC analysis. Radiology 1999;12:445-452
48. Tabuchi T, Itoh K, Ohshio G, et al. Tumor staging of pancreatic adenocarcinoma using early- and late-phase helical CT. AJR 1999;173:375-380
49. Nelson RC, Brink JA, Silverman PM. Helical computed tomography of the abdomen and pelvis. In: Silverman PM, ed. Multislice CT (MSCT): a practical approach to clinical protocols. Philadelphia: Lippincott, Williams and Wilkins, 2002:169-230
50. Raptopoulos V, Steer ML, Sheiman RG, Vrachliotis TG, Gougoutas CA, Movson JS. The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: correlation with findings at surgery. AJR 1997;168:971-977
51. Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000;356:190-193
52. Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000;52:367-371
53. Legmann P, Vignaux O, Dousset B, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR 1998;170:1315-1322
54. Habr F, Akerman P. Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. Front Biosci 2000;5:E30-35
55. Harewood GC, Wiersema MJ. Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am J Gastroenterol 2002;97:1386-1391
56. Wiersema MJ. Accuracy of endoscopic ultrasound in diagnosing and staging pancreatic carcinoma. Pancreatology 2001;1:625-632
57. Shin HJ, Lahoti S, Sneige N. Endoscopic ultrasound-guided fine-needle aspiration in 179 cases: the M. D. Anderson Cancer Center experience. Cancer 2002;96:174-180
58. Diederichs CG, Shreve PD. Pancreatic cancer. In: Wieler HJ, Coleman RE, eds. PET in clinical onoclogy. Darmstadt: Steinkopff Verlag, 2000:211-224
59. Steinert HC, Kubik-Huch R, Kacl G. Tumors of the abdomen and pelvis. In: von Schulthess GK, ed. Clinical positron emission tomography: correlation with morphological cross-sectional imaging. Philadelphia: Lippincott Williams and Wilkins, 2000:195-206
60. Clark LR, Jaffe MH, Choyke PL, et al. Pancreatic imaging. Radiol Clin North Am 1985;23:489-501
61. Kim T, Murakami T, Takamura M, et al. Pancreatic mass due to chronic pancreatitis: correlation of CT and MR imaging features with pathologic findings. AJR 2001;177:367-371
62. Vitellas KM, Keogan MT, Spritzer CE, Nelson RC. MR cholangiopancreatography of bile and pancreatic duct abnormalities with emphasis on the singleshot fast spin-echo technique. RadioGraphics 2000;20:939-957; quiz 1107-1108, 1112
63. Brand B, Pfaff T, Binmoeller KF, et al. Endoscopic ultrasound for differential diagnosis of focal pancreatic lesions, confirmed by surgery. Scand J Gastroenterol 2000;35:1221-1228
64. Harewood GC, Wiersema LM, Halling AC, Keeney GL, Salamao DR, Wiersema MJ. Influence of EUS training and pathology interpretation on accuracy of EUS-guided fine needle aspiration of pancreatic masses. Gastrointest Endosc 2002;55:669-673
65. Zimny M, Schumpelick V. Fluorodeoxyglucose positron emission tomography (FDG-PET) in the differential diagnosis of pancreatic lesions [in German]. Chirurg 2001;72:989-994
66. Diederichs CG, Staib L, Vogel J, et al. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000;20:109-116
67. Nitzsche EU, Hoegerle S, Mix M, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med 2002;29:237-242
68. Nakamoto Y, Higashi T, Sakahara H, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-2554
69. Loyer E, David C, DuBrow RA. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging 1996;21:202-206
70. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR 1997;168:1439-1443
71. Gress FG, Hawes RH, Savides TJ, et al. Role of EUS in the preoperative staging of pancreatic cancer: a large single-center experience. Gastrointest Endosc 1999;50:786-791
72. Hochwald SN, Rofsky NM, Dobryansky M, Shamamian P, Marcus SG. Magnetic resonance imaging with magnetic resonance cholangiopancreatography accurately predicts resectability of pancreatic carcinoma. J Gastrointest Surg 1999;3:506-511
73. Trede M, Rumstadt B, Wendl K, et al. Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors. Ann Surg 1997;226:393-405
74. Arslan A, Buanes T, Geitung JT. Pancreatic carcinoma: MR, MR angiography and dynamic helical CT in the evaluation of vascular invasion. Eur J Radiol 2001;38:151-159
75. Brugge WR, Lee MJ, Kelsey PB, Schapiro RH, Warshaw AL. The use of EUS to diagnose malignant portal venous system invasion by pancreatic cancer. Gastrointest Endosc 1996;43:561-567
76. Tio TL, Sie LH, Kallimanis G, et al. Staging of ampullary and pancreatic carcinoma: comparison between endosonography and surgery. Gastrointest Endosc 1996;44:706-713
77. Calculli L, Casadei R, Diacono D, et al. Role of spiral computerized tomography in the staging of pancreatic carcinoma [in Italian]. Radiol Med (Torino) 1998;95:344-348
78. Murakami K, Nawano S, Moriyama N, et al. Staging of pancreatic ductal adenocarcinoma using dynamic MR imaging [in Japanese]. Nippon Igaku Hoshasen Gakkai Zasshi 1997;57:596-601
79. van Delden OM, de Wit LT, Nieveen van Dijkum EJ, Reeders JW, Gouma DJ. Laparoscopic ultrasonography for abdominal tumor staging. Eur Radiol 1998;8:1405-1408
80. Jimenez RE, Warshaw AL, Fernandez-Del Castillo C. Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg 2000;7:15-20
81. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 2000;135:409-414
82. Pisters PW, Lee JE, Vauthey JN. Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325-337
83. Jadvar H, Fischman AJ. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 2001;26:254-259